The PROSPECT-Lung trial, a large multicenter study, aims to evaluate the role of immunotherapy before and after surgery in resectable non-small cell lung cancer, determining if it improves survival and cancer-free status. It seeks to answer whether perioperative immunotherapy is more effective than adjuvant therapy alone. The trial is part of the NCI's Clinical Trials Innovation Unit, aiming to simplify trials and improve their efficacy.